Avinger launches post-market study comparing OCT to IVUS in PAD treatments
Avinger (NSDQ:AVGR) said today it launched a post-market study comparing optical coherence tomography to intravascular ultrasound as used during interventions in the peripheral arteries. The Redwood City, Calif.-based company’s Lumivascular tech, including its Pantheris image-guided atherectomy device and Ocelot image-guided chronic total occlusion crossing catheters, use OCT for real-time intravascular imaging during interventions to treat peripheral artery disease. “As a regular user of diagnostic IVUS to plan treatment and assess results after the delivery of therapy, I have found that having an intrava...
Source: Mass Device - June 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Imaging Vascular Avinger Source Type: news

World No Tobacco Day 2018: Tobacco breaks hearts
Cairo, Egypt, 31 May – Every year, on 31 May, the World Health Organization (WHO) and partners mark World No Tobacco Day, highlighting the health and other risks associated with tobacco use, and advocating for effective policies to reduce tobacco consumption. This year, World No Tobacco Day focuses on tobacco and heart disease. The campaign’s slogan is “Tobacco breaks hearts. Choose health, not tobacco”. Tobacco use is one of the leading causes of premature death and disability worldwide. It is also a key risk factor for the development of coronary heart disease, stroke and peripheral vascular dise...
Source: WHO EMRO News - May 26, 2018 Category: Middle East Health Source Type: news

Avinger wins FDA nod for next-gen Pantheris
Avinger (NSDQ:AVGR) said today it won FDA 510(k) clearance for its next-gen Pantheris lumivascular atherectomy system, which it touts as the first image-guided atherectomy device designed for treating peripheral artery disease. Redwood City, Calif.-based Avinger said the newly cleared Pantheris device features a simpler, single-balloon system designed both for apposition and blood flow occlusion and improved pushability and tissue storage capacity. The system is designed to treat blocked peripheral blood vessels, using its Lumivascular optical coherence tomography technology, the company added. “We are exci...
Source: Mass Device - May 23, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Catheters Food & Drug Administration (FDA) Regulatory/Compliance Vascular Avinger Source Type: news

Statins in Peripheral Artery Disease: Why Are We Waiting? Statins in Peripheral Artery Disease: Why Are We Waiting?
Should high-intensity statin therapy be prescribed for patients with atherosclerotic peripheral artery disease?Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Nigeria:Tobacco Consumption Contributes 12% Deaths From Heart Diseases - NHF
[This Day] Tobacco use and second-hand smoke is a major risk factor for cardiovascular disease (CVD), including coronary heart disease, stroke and peripheral vascular disease; contributing about 12 per cent death from heart disease, the Nigerian Heart Foundation (NHF), has said. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 17, 2018 Category: African Health Source Type: news

SurModics acquires Embolitech thrombectomy tech for $5m
SurModics (NSDQ:SRDX) said today it inked a deal with Embolitech to acquire its thrombectomy platform the and associated intellectual property in a deal worth $5 million up front, with additional payments based on regulatory milestones. The newly acquired tech platform is designed for use in the peripheral vasculature to remove hard blood clots, Eden Prairie, Minn.-based SurModics said. SurModics added that it plans to leverage its design, development and manufacturing capabilities to advance the platform into different peripheral and vascular applications. “We are pleased to sign an agreement with Surmodic...
Source: Mass Device - May 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Catheters Mergers & Acquisitions Vascular SurModics Inc. Source Type: news

FDA Expands Indication for IN.PACT Admiral Balloon in PAD FDA Expands Indication for IN.PACT Admiral Balloon in PAD
The IN.PACT Admiral DCB is now indicated to treat long superficial femoral artery lesions up to 360 mm in patients with peripheral artery disease.FDA Approvals (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 26, 2018 Category: Surgery Tags: Cardiology News Alert Source Type: news

In-home, wearable-supported mobility program for artery disease patients falls short
A study published yesterday in JAMA found that, compared to normal care, a home-based exercise program employing wearables and telephone coaching did not help patients with peripheral artery disease (PAD) improve their walking performance over a nine-month period. (Source: mobihealthnews)
Source: mobihealthnews - April 25, 2018 Category: Information Technology Source Type: news

Medin Technologies taps Donaldson as CEO | Personnel Moves – April 25, 2017
Medin Technologies said last week it tapped Bill Donaldson as its new chief executive officer, replacing Andy Novotny who is resigning from his position at the head of the company. Prior to joining Medin Technologies, Donaldson served as president of Jeld-Wen Canada, leading the business unit during its parent company’s initial public offering, Totowa, N.J.-based Medin Technologies said. Donaldson has also held positions with Circor’s KF Industries, Sagebrush Pipeline, Spence Engineering and Danaher’s Kollmorgen. “I cannot imagine a more important and exciting time to join Medin Technologies. With a...
Source: Mass Device - April 25, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat AdvaMed althea bectondickinson Cook Medical CoreLink GI Dynamics medintechnologies paxerahealth Profound Medical Inc. Ra Medical Smith & Nephew Wound Management Technologies Source Type: news

Exercise Intervention Doesn't Improve Walking Ability in PAD
TUESDAY, April 24, 2018 -- For patients with peripheral artery disease (PAD), a home-based exercise intervention does not improve walking ability over nine months compared with usual care, according to a study published in the April 24 issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2018 Category: Pharmaceuticals Source Type: news

Effect of a home-based exercise program with wearable activity monitor, telephone coaching on walking endurance for peripheral artery disease
(JAMA Network) A home-based exercise program that consisted of a wearable   activity monitor and telephone coaching to promote walking by patients with peripheral artery disease didn't improve walking endurance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 24, 2018 Category: International Medicine & Public Health Source Type: news

A wearable device intervention to increase exercise in peripheral artery disease
(Northwestern University) A home-based exercise program, consisting of wearables and telephone coaching, did not improve walking endurance for patients with peripheral artery disease, according to a study published in JAMA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 24, 2018 Category: International Medicine & Public Health Source Type: news

Can New Indication Give Medtronic Edge in DCB?
Medtronic is entering  a bold new chapter in the continued evolution of its drug-coated balloon technology (DCB). The Dublin-based firm said on Monday, that it received a nod from FDA for the IN.PACT Admiral DCB to treat long superficial femoral artery (SFA) lesions up to 360mm in patients suffering from peripheral artery disease (PAD).  Approval was based on clinical data from the complex lesion imaging cohorts of the IN.PACT Global Study, including long lesion, in-stent restenosis, and chronic total occlusion groups with lesion lengths greater than 180mm. Across these groups, a total of 227 subjects with mean l...
Source: MDDI - April 24, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

FDA approves Medtronic ’ s drug-coated balloon to treat long superficial femoral artery lesions
The FDA approved Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon to treat long superficial femoral artery lesions up to 360mm in patients with peripheral artery disease, the medtech giant touted today. In a 227-patient global trial, participants treated with Medtronic’s drug-device combination therapy had a one-year patency rate of 89.1% and a clinically-driven target revascularization rate of 7.1%. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves Medtronic’s drug-coated balloon to treat long superficial femoral artery lesions appeared first on MassDevic...
Source: Mass Device - April 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Vascular Wall Street Beat Medtronic Source Type: news

Increased Risk of Peripheral Artery Disease With HIV Infection Increased Risk of Peripheral Artery Disease With HIV Infection
HIV infection is associated with a significantly increased risk of peripheral artery disease (PAD), according to results from the Veterans Aging Cohort Study (VACS).Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 18, 2018 Category: Infectious Diseases Tags: Cardiology News Source Type: news

Bioelectronic Medicine: Targeting Inflammatory Disease with Electricity
We presented positive initial results in Crohn’s disease at the 2016 United European Gastroenterology meeting: six of the eight patients had seen a substantial reduction in their disease activity index scores, and three were in remission from the disease. As SetPoint looks ahead, several chronic disease areas are emerging as key bioelectronic medicine therapy targets, and our company is exploring a number of these. One of our preclinical programs explores bioelectronic medicine’s potential role as a treatment for MS.   New Target: Multiple Sclerosis In late 2017, SetPoint presented positive data from a s...
Source: Mass Device - April 17, 2018 Category: Medical Devices Authors: Anthony Arnold Tags: Bioelectronic Medicine Clinical Trials Neuromodulation/Neurostimulation SetPoint Medical Sponsored Content Source Type: news

No Limb-Ischemia Wound-Healing Gains From Gene Therapy: STOP-PAD No Limb-Ischemia Wound-Healing Gains From Gene Therapy: STOP-PAD
Although the novel treatment didn't improve ulcers or other wounds from critical limb ischemia, the study highlights the microvasculature's important role in peripheral artery disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 12, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Avinger touts 1st use of extended-nosecone Pantheris cath
Avinger (NSDQ:AVGR) said today it launched its Pantheris lumivascular atherectomy system with extended nosecone in the European Union, touting that the device has been used in its first human patients. The device was used by Dr. Arne Schwindt in treating peripheral artery disease in three patients at Münster, Germany’s St. Franziskus Hospital, the Redwood City, Calif.-based company said. “Despite the difficult nature of these particular interventions, I was able to safely and effectively achieve positive outcomes for these patients using the new version of Pantheris with the extended nosecone. I ...
Source: Mass Device - March 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Catheters Vascular Avinger Source Type: news

Reflow Medical launches chronic total occlusion study of Wingman caths
Reflow Medical said yesterday it launched a clinical study of its Reflow Wingman catheters exploring the device’s ability to cross chronic total occlusions in peripheral lesions. The first patients in the study, dubbed the Wing-It trial, have already been enrolled, the San Clemente, Calif.-based company said. Enrollments took place at Springfield, Ill.’s St. John’s Hospital Prairie by Dr. Nilesh Goswami and at Bradenton, Fla.’s Bradenton Cardiology Center by Dr. S. Mathews. “Reflow is excited to be conducting this study to support expanded treatment options for physicians,” CEO Isa ...
Source: Mass Device - March 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Catheters Clinical Trials Vascular ReFlow Medical Source Type: news

Cardiovascular Systems touts 18-month Liberty PAD study data
Cardiovascular Systems (NSDQ:CSII) today released 18-month results from the Liberty 360° study of peripheral artery disease interventions, touting high freedom from adverse events and amputations. Results from the study were presented by Dr. William Gray of Wynnewood, Penn.’s Lankenau Heart Institute at the Cardiovascular Research Technologies 2018 interventional cardiology conference in Washington D.C., the St. Paul, Minn.-based company said. “The 18-month Liberty 360° results continue to show that PVI, including the use of orbital atherectomy, can lead to amputation free survival for patients wit...
Source: Mass Device - March 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Cardiovascular Systems Inc. Source Type: news

LimFlow hopes to give end-stage CLI patients an alternative to amputation with its pDVA system
Earlier this year the FDA accepted LimFlow’s Percutaneous Deep Vein Arterialization system into its Breakthrough Device Program. CEO Dan Rose is hopeful that that designation, along with an increased feasibility study size, will help get the company’s pDVA product to critical limb ischemia patients in the US facing limb amputations with no other options. “There are over 270,000 ischemic major amputations in U.S. and Europe every year and these patients have no option today,” Rose said in an interview with MassDevice.com. “We’re really trying to provide a new solution for patients who hav...
Source: Mass Device - March 2, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Food & Drug Administration (FDA) Vascular LimFlow Source Type: news

Surmodics, Abbott ink licensing deal worth up to $92M
Med-tech firm Surmodics Inc. has landed a licensing deal with health care giant Abbott Laboratories Inc. that could be worth up to $92 million, the companies announced Tuesday. Eden Prairie-based Surmodics will exclusively license its SurVeil drug-coated balloon device to Abbott (NYSE: ABT). Surmodics is testing the device as a treatment for peripheral artery disease. Under terms of the agreement, Abbott will also get rights to negotiate a licensing deal for a separate drug-coated balloon device… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 27, 2018 Category: Biotechnology Authors: Katharine Grayson Source Type: news

Abbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon
COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U. AGREEMENT COMPLEMENTS AND EXTENDS ABBOTT'S BROAD LINE OF VASCULAR CARE PRODUCTS AND DEMONSTRATES VALUE OF SURMODICS' PROPRIETA... Devices, Interventional, Licensing Abbott, Surmodics, Drug-Coated Balloon, SurVeil, peripheral artery disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 27, 2018 Category: Pharmaceuticals Source Type: news

Abbott, Surmodics ink $25m deal for drug-coated balloon tech
Abbott (NYSE:ABT) is slated to pay $25 million upfront for the global commercialization rights to Surmodics‘ (NSDQ:SRDX) SurVeil drug-coated balloon, the companies announced today. The company’s drug-device combo, which is in pivotal trials in the U.S., is designed to treat peripheral artery disease in the superficial femoral artery. According to the deal, Abbott could also negotiate agreements for Surmodics’ below-the-knee and arteriovenous fistula drug-coated balloons, which are still in pre-clinical development. Get the full story at our sister site, Drug Delivery Business News. The post Abbo...
Source: Mass Device - February 27, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Vascular Wall Street Beat Abbott SurModics Inc. Source Type: news

Corindus wins FDA 510(k) PVI indication for CorPath GRX
Corindus Vascular Robotics (OTC:CVRS) said today it won FDA 510(k) clearance for its CorPath GRX system, now indicated for use in peripheral vascular interventions. The Waltham, Mass.-based company touts the CorPath system as the first and only FDA-cleared robotic device cleared for both percutaneous coronary interventions and peripheral vascular interventions. “My colleagues and I have seen first-hand how CorPath GRX can overcome the challenges of manual PCI and I am excited to apply the capabilities of robotics to effectively treat PAD patients. As a training site for future robotic interventionalists, I ...
Source: Mass Device - February 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Robotics Surgical Corindus Vascular Robotics Source Type: news

Siemens Healthineers taps ex-Abbott Vascular prez Nath to lead lab diag biz | Personnel Moves January 30, 2018
Siemens (NYSE:SI) Healthineers said today it tapped former Abbott (NYSE:ABT) Vascular president Dr. Deepak Nath as its new laboratory diagnostics business president, taking over for Franz Walt who operated as president from 2014 to 2017. Nath spent 10 years with Abbott, serving most recently as its vascular division president and as an executive officer of the company, and as president of the molecular diagnostics division prior to that. He also operated as GM of Ibis Biosciences, and has held positions at Amgen (NSDQ:AMGN) and McKinsey. “Siemens Healthineers seeks to benefit from market oppo...
Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Abbott aligntechnology Amgen Cardiovascular Systems Inc. CHF Solutions Inc. Cook Group Inc. Endologix Hill-Rom Holdings Inc. Invetech johnsonandjohnson lohmannandrauscher Medtronic Neuromod Devices Novar Source Type: news

Medtronic ’ s In.Pact Admiral drug-coated balloon succeeds in two-year study, critical limb ischemia analysis
Medtronic (NYSE:MDT) touted data today from a two-year study of its In.Pact Admiral drug-coated balloon in patients with peripheral artery disease in Japan, as well as the results from a critical limb ischemia subgroup analysis from its In.Pact Global trial. The company’s In.Pact SFA Japan study enrolled 100 patients and randomized them to receive either the drug-coated balloon or plain balloon angioplasty. Get the full story at our sister site, Drug Delivery Business News. The post Medtronic’s In.Pact Admiral drug-coated balloon succeeds in two-year study, critical limb ischemia analysis appeared first on...
Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Medtronic Source Type: news

Medtronic closes $28m buyout of QT Vascular ’ s Chocolate PTA balloon
Medtronic (NYSE:MDT) closed the $28 million acquisition of the Chocolate PTA non-drug-coated balloon made by QT Vascular, after taking an option on the device last year. In February 2017 the companies inked a 5-year deal calling for Medtronic to distribute the Chocolate PTA device. Last May the Fridley, Minn.-based medical device giant agreed to the option deal on Chocolate PTA, which was triggered in part after QT Vascular successfully shifted production to a third-party contract manufacturer. “Through our distribution agreement with QT Vascular, we have seen a lot of excitement from ph...
Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Vascular Wall Street Beat Medtronic peripheral QT Vascular Source Type: news

Vascular Insights(R) Announces New Chief Executive Officer
James P. Ott to Join Vascular Insights® as President & CEO QUINCY, Mass., Jan. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Vascular Insights® announced that its Board of Directors has appointed James P. Ott as President and CEO. Ji... Devices, Interventional, Personnel Vascular Insights, ClariVein, peripheral vascular disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 26, 2018 Category: Pharmaceuticals Source Type: news

Giving new medical tech a kickstart at University of Pittsburgh
(University of Pittsburgh) The University of Pittsburgh's Center for Medical Innovation (CMI) awarded grants totaling $115,000 to five engineering and medicine groups through its 2017 Round-2 Pilot Funding Program for Early Stage Medical Technology Research and Development. The latest funding proposals include proposed solutions to conditions such as peripheral artery disease, pulmonary fibrosis, improving auditory pathology detection, improved wound healing and repair, and a better means to perform root canal surgery. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 22, 2018 Category: Biology Source Type: news

Peripheral Vascular Disease (PVD Symptoms, Signs, Causes, Treatments)
Title: Peripheral Vascular Disease (PVD Symptoms, Signs, Causes, Treatments)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 1/19/2018 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - January 19, 2018 Category: Cardiology Source Type: news

BD Clears Final Regulatory Hurdle for Bard Deal
Becton, Dickinson and Company (BD) said Thursday that its pending acquisition of C.R. Bard has been cleared by the Ministry of Commerce of the People's Republic of China (MOFCOM). Franklin Lakes, NJ-based BD now plans to close the deal Friday, so long as the MOFCOM also approves Merit Medical as the buyer for its soft tissue core needle biopsy product line divestiture. MOFCOM cleared the Bard acquisition on the condition that BD divests its soft tissue core needle biopsy product line. This was the final regulatory approval needed to complete the Bard deal, said Vincent Forlenza, chairman and CEO of BD.  BD broke ...
Source: MDDI - December 28, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Medical Device Business Cardiovascular Source Type: news

Avinger bids for FDA nod for new Pantheris atherectomy device
A day after announcing CE Mark approval for the next generation of its Pantheris atherectomy device, Avinger (NSDQ:AVGR) said it’s seeking a similar nod from the FDA. The bid for 510(k) clearance from the federal safety watchdog for the image-guided device covers new features including a simpler, single-balloon system designed both for apposition and blood flow occlusion and improved pushability and tissue storage capacity. The new Pantheris is designed to treat blocked peripheral blood vessels, using Avinger’s Lumivascular optical coherence tomography technology. “We have received invaluab...
Source: Mass Device - December 21, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Food & Drug Administration (FDA) Regulatory/Compliance Avinger peripheral Source Type: news

Avinger wins CE Mark for next-gen Pantheris atherectomy device
Avinger (NSDQ:AVGR) said today that it won CE Mark approval in the European Union for the next generation of its Pantheris image-guided atherectomy device. Redwood City, Calif.-based Avinger said the new device features a simpler, single-balloon system designed both for apposition and blood flow occlusion and improved pushability and tissue storage capacity. It’s designed to treat blocked peripheral blood vessels, using its Lumivascular optical coherence tomography technology. “CE Marking approval to market and sell our next generation of Pantheris in Europe and other CE Mark countries represents an i...
Source: Mass Device - December 20, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Imaging Regulatory/Compliance Avinger peripheral Source Type: news

PQ Bypass wins IDE nod for Detour percutaneous femoropopliteal bypass study
PQ Bypass said today it won FDA investigational device exemption approval to launch a pivotal clinical trial of its Detour percutaneous femoropopliteal bypass system designed to treat patients with peripheral artery disease. The company’s Detour II clinical trial will look to enroll up to 292 patients with lower limb ischemia due to long blockages over 15 cm in the superficial femoral artery, the Sunnyvale, Calif.-based company said. “We worked closely with the FDA, leading physicians and healthcare administrators to design a trial that we expect to demonstrate the total value of this unique approach to tr...
Source: Mass Device - December 13, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Regulatory/Compliance Stent Grafts Vascular PQ Bypass Source Type: news

Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO ® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 11, 2017 Category: Pharmaceuticals Source Type: news

7 medtech stories we missed this week: Dec. 8, 2017
[Image from unsplash.com]From Minimus Spine’s European distribution deal to Stimwave receiving FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Minimus Spine inks EU distribution deal Minimus Spine announced in a Dec. 4 press release that it has signed its first European distribution deal with Italian company Moss and has completed its first commercial order. Moss has exclusive distribution rights to distribute in Italy, Germany, Switzerland and the U.K. 2. Elanix, Dermacon sign wound management development deal Elanix Biotechnologies and Dermacon...
Source: Mass Device - December 8, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiac Assist Devices Cardiovascular Diagnostics Food & Drug Administration (FDA) Hospital Care Pain Management Regulatory/Compliance Cagent Vascular CSA Medical Inc. Dermacon Elanix Life Spine Inc. MedTech Minimus Spin Source Type: news

Molecular beacon signals low oxygen with ultrasound
(University of Illinois at Urbana-Champaign) Areas of hypoxia, or low oxygen in tissue, are hallmarks of fast-growing cancers and of blockages or narrowing in blood vessels, such as stroke or peripheral artery disease. University of Illinois researchers have developed a way to find hypoxic spots noninvasively in real time. The researchers developed an oxygen-sensitive molecular beacon that emits ultrasound signals in response to light, a process called photoacoustic imaging. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 8, 2017 Category: Cancer & Oncology Source Type: news

Improving walking for people with peripheral artery disease
A study of older adults with peripheral artery disease showed that treadmill exercise for 12 weeks improved walking distance, but a drug called GM-CSF did not. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - December 4, 2017 Category: Consumer Health News Source Type: news

Ra Medical co-founder Burstein touts innovation, planning and caring as keys to success for medtech execs
This year has been an exciting one for Ra Medical, maker of the Dabra arteriosclerosis laser designed to treat peripheral artery disease. In May, the Carlsbad, Calif.-based company received a nod from the FDA for the Dabra, clearing it for sale in the US – something it had applied for approximately three years prior. And in September, the company revealed plans for a new funding round looking to raise up to $15 million to support the newly cleared technology. The path to commercialization has been a long, and satisfying, journey for co-founder and executive vice president Melissa Burstein. She credits the c...
Source: Mass Device - December 1, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Ra Medical Source Type: news

Scientists find key to regenerating blood vessels
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a signaling pathway that is essential for angiogenesis, the growth of new blood vessels from pre-existing vessels. The findings, published in Nature Communications, may improve current strategies to improve blood flow in ischemic tissue, such as that found in atherosclerosis and peripheral vascular disease associated with diabetes. (Source: World Pharma News)
Source: World Pharma News - November 23, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Scientists find key to regenerating blood vessels
(Sanford-Burnham Prebys Medical Discovery Institute) Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a signaling pathway that is essential for angiogenesis, the growth of new blood vessels from pre-existing vessels. The findings, published in Nature Communications, may improve current strategies to improve blood flow in ischemic tissue, such as that found in atherosclerosis and peripheral vascular disease associated with diabetes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 23, 2017 Category: Cancer & Oncology Source Type: news

Avinger slashes jobs, Q3 sales down 61%
Avinger (Nasdaq:AVGR) – maker of the Lumivascular image-guided, catheter-based system to treat peripheral artery disease (PAD) – continued to experience declining sales as it retrenched during the third quarter, according to its newest earnings report. The Redwood, Calif.–based company has been cutting jobs and other costs– and focusing on existing accounts and winning FDA clearance for new devices. Avinger had 73 employees, including 20 sales employees, as of Oct. 15. The number is down nearly two-thirds from the 197 employees, including 70 in sales, that the company had at the end of 201...
Source: Mass Device - November 13, 2017 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News Cardiovascular Catheters Imaging News Well Avinger Source Type: news

New Analyses Presented At AHA 2017 Show Repatha ® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks
Data Support Use of Repatha to Reduce Risk of Recurrent Cardiovascular Events in Patients With History of Multiple Heart Attacks Additional Analysis Found That Patients With More Recent Heart Attacks Experienced Substantial Risk Reductions With Repatha Repatha Benefit in Peripheral Artery Disease Patients Presented at AHA Scientific Sessions 2017 and Simultaneously Published in "Circulation" THOUSAND OAKS, Calif., Nov. 13, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced five new subgroup analyses from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that s...
Source: Amgen News Release - November 13, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

PCSK9 Inhibitor improves outcomes for patients with peripheral artery disease
(Brigham and Women's Hospital) A new sub-analysis of the FOURIER clinical trial, however, now offers information on the safety and effectiveness of giving the PCSK9 inhibitor evolocumab on top of statin therapy to patients with peripheral artery disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2017 Category: International Medicine & Public Health Source Type: news

PCSK9 Inhibitor Improves Outcomes for Patients with Peripheral Artery Disease
LDL-cholesterol-lowering drug evolocumab reduced risk of major cardiovascular events and major adverse limb events among peripheral artery disease sub-population from the FOURIER trial. (Source: BWH News)
Source: BWH News - November 13, 2017 Category: Hospital Management Source Type: news

PCSK9 Inhibitor Improves Outcomes for Patients with Peripheral Artery Disease
LDL-cholesterol-lowering drug evolocumab reduced risk of major cardiovascular events and major adverse limb events among peripheral artery disease sub-population from the FOURIER trial. (Source: BWH for Journalists)
Source: BWH for Journalists - November 13, 2017 Category: Research Source Type: news

Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha ® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017
Late-Breaking Repatha Presentations Assess Impact on Peripheral Artery Disease and Heart Attack Patients THOUSAND OAKS, Calif., Nov. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new analyses will be presented from the Repatha® (evolocumab) cardiovascular outcomes study, including analyses investigating the efficacy of Repatha in high-risk patients with peripheral artery disease (PAD) and those who have experienced a prior heart attack. In total, five distinct analyses from the Repatha cardiovascular outcomes study (FOURIER), including two accepted for late-breaker scientific sessions, wil...
Source: Amgen News Release - November 6, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news